CRM Induced Pluripotent Stem (iPS) Cell Material Transfer Agreement
This document in PDF format (146KB)
- Parties:
- PROVIDER: Center for Regenerative Medicine, National Institutes of Health,
Bethesda, MD (NIH/CRM), a trans-NIH initiative administratively housed within
the National Institute of Arthritis and Musculoskeletal and Skin Diseases
(NIAMS)/NIH.
- RECIPIENT:
- RECIPIENT SCIENTIST:
- Definitions:
- COMMERCIAL PURPOSES: The use, sale, lease or license of a material for fee
in connection with any business or undertaking intended for profit.
- INDUCED PLURIPOTENT STEM CELLS ("iPS CELLS"): Adult cells (such as
skin cells or lymphoblasts) "reprogrammed" to assume an embryonic stem cell-like
state, by being forced to express genes and factors important for maintaining
the defining properties of embryonic stem cells.
- MATERIAL(S): ORIGINAL MATERIAL, PROGENY, and UNMODIFIED
DERIVATIVES.
- MODIFIED DERIVATIVES: Substances that are not intact cells that RECIPIENT
isolated or derived from NON-PLURIPOTENT MODIFICATIONS or
PLURIPOTENT MODIFICATIONS and that are not UNMODIFIED
DERIVATIVES.
- NON-PLURIPOTENT MODIFICATIONS: Cells that are created by the
RECIPIENT from ORIGINAL MATERIAL, PROGENY or PLURIPOTENT
MODIFICATIONS, but only if such cells are NOT capable of responding to
extrinsically acting cues (such as growth factors, changing media conditions, and
other similar cues) to differentiate into various cell types from each of the three
embryonic germ layers (endoderm, ectoderm, mesoderm). For clarity, NONPLURIPOTENT
MODIFICATIONS may be multipotent, restricted progenitor cells,
or may be terminally differentiated cells, but are NOT pluripotent. NONPLURIPOTENT
MODIFICATIONS may or may not have been genetically
manipulated by the RECIPIENT in the manner described in the definition of
PLURIPOTENT MODIFICATIONS.
ORIGINAL MATERIAL(S): The iPS CELLS provided by the PROVIDER to the
RECIPIENT, as described in Appendix ONE.
- PLURIPOTENT MODIFICATIONS: iPS CELLS that are created by the
RECIPIENT from ORIGINAL MATERIAL or PROGENY. PLURIPOTENT
MODIFICATIONS differ from ORIGINAL MATERIAL and PROGENY as a result
of a manipulation (genetic or otherwise) to the ORIGINAL MATERIAL or
PROGENY performed by the RECIPIENT. Some examples of such genetic
manipulations include: integration of a reporter gene, or correction of a genetic
defect of the ORIGINAL MATERIAL. For clarity, PLURIPOTENT
MODIFICATIONS are capable of self-renewal in culture and of responding to
extrinsically acting cues (such as growth factors, changing media conditions, and
other similar cues) to differentiate into various cell types from each of the three
embryonic germ layers (endoderm, ectoderm, mesoderm).
- PROGENY: Unmodified descendant iPS Cells from the ORIGINAL MATERIAL.
Progeny retain the ability to self-replicate and the ability to differentiate into cell
types from all three germ layers.
- THIRD PARTY or THIRD PARTIES: Any person or entity that is not a PARTY to
this AGREEMENT and is not a RECIPIENT.
- UNMODIFIED DERIVATIVES: Substances that are not intact cells that
RECIPIENT either: (a) isolated or derived from ORIGINAL MATERIAL,
PROGENY or other UNMODIFIED DERIVATIVES or (b) isolated or derived from
NON-PLURIPOTENT MODIFICATIONS, PLURIPOTENT MODIFICATIONS or
MODIFIED DERIVATIVES that are indistinguishable from substances that could
have been isolated or derived from ORIGINAL MATERIAL, PROGENY or other
UNMODIFIED DERIVATIVES.
-
Terms and Conditions of this Agreement:
- The RECIPIENT agrees that the MATERIAL:
- will not be used in human subjects, in clinical trials, or for diagnostic purposes
involving human subjects without the written consent of the PROVIDER;
- will be used only in compliance with applicable laws and regulations;
- will, in the case of entities receiving funding from agencies of the United
States to conduct human stem cell research, be used only in compliance with
applicable National Institutes of Health Guidelines on Human Stem Cell
Research: http://stemcells.nih.gov/policy;
- will not be used in research in which the MATERIALS are introduced into nonhuman
primate blastocysts;
- will not be used in research involving the breeding of animals where the
introduction the MATERIALS may contribute to the germ line; and
- is subject to the additional terms and conditions in the appendices attached
hereto.
- The RECIPIENT acknowledges that the MATERIAL may be the subject of a patent
application or covered by patent rights in one or more countries. Except as provided
in this Agreement, no express or implied licenses or other rights are provided to use
the MATERIAL, NON-PLURIPOTENT MODIFICATIONS, PLURIPOTENT
MODIFICATIONS, MODIFIED DERIVATIVES or any related patents for
COMMERCIAL PURPOSES.
- No ownership rights to the MATERIAL, including any MATERIAL contained or
incorporated in NON-PLURIPOTENT MODIFICATIONS, PLURIPOTENT
MODIFICATIONS or MODIFIED DERIVATIVES are conveyed to the RECIPIENT
under this Agreement.
- Exclusive of any third-party rights that may exist, the RECIPIENT retains ownership
of: (a) NON-PLURIPOTENT MODIFICATIONS and (b) those substances created
through the use of the MATERIAL, NON-PLURIPOTENT MODIFICATIONS or
PLURIPOTENT MODIFICATIONS, but which are not PROGENY or UNMODIFIED
DERIVATIVES.
- Unless restricted by Appendix TWO or Appendix THREE, The RECIPIENT may
transfer MATERIAL to other nonprofit or governmental parties if permission from the
PROVIDER is first obtained.
- RECIPIENT shall have the right to nonexclusively distribute:
- NON-PLURIPOTENT MODIFICATIONS or PLURIPOTENT MODIFICATIONS
subject to Appendix TWO and Appendix THREE restrictions, if any, and the
following term:
- In the event that RECIPIENT enters into negotiations to provide or
license PLURIPOTENT MODIFICATIONS to a THIRD PARTY for
COMMERCIAL PURPOSES, then RECIPIENT will notify that
THIRD PARTY of PROVIDER’s ownership of MATERIALS that are
contained or incorporated within the PLURIPOTENT
MODIFICATIONS. It is recognized by the RECIPIENT that such
COMMERCIAL PURPOSES may require a license from
PROVIDER, who has no obligation to grant a license to any
ownership interest in MATERIAL incorporated in the
PLURIPOTENT MODIFICATIONS.
- MODIFIED DERIVATIVES subject to Appendix TWO and Appendix THREE
restrictions, if any, and the following terms:
- RECIPIENT will transfer such substances, and sufficient rights to
use them, to other academic and governmental research
institutions for internal research purposes at nominal cost, and will
implement arrangements to effect such transfers.
- There is no restriction on RECIPIENT’s development of commercial products
resulting from the knowledge gained from research using the MATERIAL,
MODIFIED DERIVATIVES, NON-PLURIPOTENT MODIFICATIONS or
PLURIPOTENT MODIFICATIONS.
- The RECIPIENT is free to file patent application(s) claiming inventions made by the
RECIPIENT through the use of the MATERIAL but agrees to notify the PROVIDER
upon filing a patent application claiming MATERIALS, NON-PLURIPOTENT
MODIFICATIONS, PLURIPOTENT MODIFICATIONS, MODIFIED DERIVATIVES or
method(s) of manufacture or use(s) of the MATERIAL.
- RECIPIENT AND RECIPIENT SCIENTIST agree not to attempt to identify or contact
the donor subject from whom the ORIGINAL MATERIAL was or may have been
derived.
- Any MATERIAL delivered pursuant to this Agreement is understood to be
experimental in nature and may have hazardous properties and its use may require
acquisition of rights from THIRD PARTIES. The PROVIDER MAKES NO
REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER
EXPRESSED OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED
WARRANTIES OF THE MATERIAL, ITS SOURCE, MERCHANTABILITY,
TRANSFER OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE
OF THE MATERIAL WILL NOT INFRINGE ANY PATENT, COPYRIGHT,
TRADEMARK, OR OTHER PROPRIETARY RIGHTS.
- For U.S. State Institutions: The RECIPIENT agrees to be responsible for any
claims, costs, damages or expenses resulting from any injury (including death)
damage, or loss that may arise solely from its use of the MATERIAL and to hold
harmless and indemnify the PROVIDER and any THIRD PARTIES having
intellectual proprietary or other rights to the MATERIAL to the extent permitted by
law.
- For all other Institutions: Except to the extent prohibited by law and except for
U.S. Government agencies (which may not agree to an indemnification obligation),
the RECIPIENT hereby agrees to hold harmless and indemnify the PROVIDER and
PROVIDER against any claim arising from the RECIPIENT’s receipt, storage,
disposition and/or use of the MATERIAL, and any claim that the RECIPIENT’s use of
the MATERIAL violates any intellectual property or other rights of a THIRD PARTY,
or violates any provision of local, national or international law, except to the extent
permitted by law when caused by the gross negligence or willful misconduct of the
PROVIDER.
- This Agreement shall not be interpreted to prevent or delay publication of research
findings resulting from the use of the MATERIAL. The RECIPIENT SCIENTIST
agrees to provide appropriate acknowledgement of the source of the MATERIAL in
all publications.
- In all oral presentations or written publications concerning the use of MATERIAL,
RECIPIENT will acknowledge PROVIDER’s contribution of ORIGINAL MATERIAL
unless requested otherwise by PROVIDER.
- Additional terms, if any, are in Appendix THREE.
SIGNATURES BEGIN ON THE NEXT PAGE
RECIPIENT expressly certifies and affirms that the contents of any statements made
herein are truthful and accurate to the best knowledge and belief, and the official signing this Agreement on behalf of RECIPIENT further certifies and affirms that he or she has the authority to do so.
FOR RECIPIENT:
Authorized Official:
[Name]
Date
[Title]
Address:
Read and understand by RECIPIENT SCIENTIST:
[Name]
Date
[Title]
FOR PROVIDER:
Authorized Official
John O’Shea, MD
Date
Scientific Director, NIAMS
Address:
Office of Technology Transfer and Development (OTTAD), NHLBI, NIH
One Rockledge Center, Suite 6070 MSC 7992
6705 Rockledge Drive
Bethesda, MD 20892-7992
Read and understand by the principal investigator:
Mahendra S. Rao, MD, PhD
Date
Director, NIH CRM
Appendix ONE
Detailed Description of ORIGINAL MATERIAL PROVIDED TO RECIPIENT
[Article I.4]
(Attach info sheet for each iPS cell line.)
Appendix TWO
Additional Terms and Conditions for RECIPIENT’s Use of MATERIALS
[Article III.5]
Original
Material |
Distribution Restrictions
(check all applicable boxes) |
Modification
Restrictions
(check all
applicable boxes) |
Source
(Include
Protocol #,
if
applicable) |
Comments |
|
—No restrictions
—for nonprofit research, or
government research use
only
For-profit entity permitted:
—internal research use only
—Commercial Purposes
—NIH license required |
Non-Pluripotent
Modifications
—Prohibited
Pluripotent
Modifications
—Prohibited |
|
|
Appendix THREE
Additional Terms
[Article III.15]
(default is "none")